CalAmp Corp. (CAMPQ)
| Market Cap | 120.57K |
| Revenue (ttm) | 264.74M |
| Net Income (ttm) | -101.35M |
| Shares Out | 1.72M |
| EPS (ttm) | -63.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,276 |
| Average Volume | 52,593 |
| Open | 0.0351 |
| Previous Close | 0.0400 |
| Day's Range | 0.0351 - 0.1100 |
| 52-Week Range | 0.0200 - 21.1600 |
| Beta | 1.73 |
| RSI | 33.09 |
| Earnings Date | Jul 18, 2024 |
About CalAmp
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, throug... [Read more]
Financial Performance
In 2022, CalAmp's revenue was $294.95 million, a decrease of -0.30% compared to the previous year's $295.84 million. Losses were -$32.49 million, 16.1% more than in 2021.
News
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and dev...
CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates
(RTTNews) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) dru...
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regula...
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicolog...
Hyped Token Launches Fall Flat as TGE Loses Mojo Ahead of Airdrop Season
Once a guaranteed pop, new token generation events are now struggling to hold value with CAMP, XAN and XPL plunging as investor enthusiasm fades and tokenomics weigh heavy.
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Camp4 Therapeutics (CAMP) Downgraded by JP Morgan to Neutral | CAMP Stock News
Camp4 Therapeutics (CAMP) Downgraded by JP Morgan to Neutral | CAMP Stock News
Camp4 Therapeutics (CAMP) Secures $100 Million in Private Placement
Camp4 Therapeutics (CAMP) Secures $100 Million in Private Placement
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $5...
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin...
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting...
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.
CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense ...
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotid...
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeuti...